A new drug developed by Australian researchers has shown promising results in reducing sepsis in a Phase II clinical trial involving 180 patients. The carbohydrate-based treatment works by calming a dangerous immune reaction that can cause organ failure. With no specific anti-sepsis therapy currently available, the findings mark a major step forward. Researchers now aim to move into Phase III trials.
Quelle: ScienceDaily | Immunsystem
Titelbild/Grafik: ScienceDaily News
Möchten Sie zu diesem Inhalt ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
Weiteres von ScienceDaily | Allergy
- Breakthrough sepsis drug shows promise in human trial
- A 20-year-old cancer vaccine may hold the key to long-term survival
- Tea can improve your health and longevity, but how you drink it matters
- Scientists may have been wrong about what causes asthma
- Why chronic gut inflammation can turn into colon cancer
- A hidden immune loop may drive dangerous inflammation with age
- Scientists solve a major roadblock holding back cancer cell therapy
- Vitamin A may be helping cancer hide from the immune system
- This sweet fruit is packed with hidden health compounds
- Scientists Found a Way to Supercharge the Immune System Against Cancer
